Literature DB >> 24911674

The history of hemophilia.

Massimo Franchini1, Pier Mannuccio Mannucci2.   

Abstract

Hemophilia A and B are rare inherited bleeding disorders characterized by the deficiency of coagulation factor VIII (FVIII) or factor IX (FIX). While the history of hemophilia dates back to the 2nd century AD, a modern description of hemophilia appeared only at the beginning of the 19th century. The discovery of "antihemophilic globulin" in the middle of the 20th century paved the way to the production of cryoprecipitate and then of FVIII and FIX concentrates. Barring the tragic consequences on the hemophilia community of the transmission of blood-borne viruses by nonvirus inactivated factor concentrates during the 1970s and 1980s, plasma-derived first and recombinant products later revolutionized the treatment of hemophilia through the widespread adoption of home treatment and prophylaxis regimens, which dramatically improved the quality of life and life expectancy of persons with hemophilia during the past decade. This article briefly reviews the most important stages of the management of hemophilia from the past century up to the present days. Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24911674     DOI: 10.1055/s-0034-1381232

Source DB:  PubMed          Journal:  Semin Thromb Hemost        ISSN: 0094-6176            Impact factor:   4.180


  18 in total

Review 1.  Extended Half-Life Factor VIII and Factor IX Preparations.

Authors:  Lukas Graf
Journal:  Transfus Med Hemother       Date:  2018-03-21       Impact factor: 3.747

Review 2.  Progress and challenges in the development of a cell-based therapy for hemophilia A.

Authors:  M E Fomin; P P Togarrati; M O Muench
Journal:  J Thromb Haemost       Date:  2014-10-31       Impact factor: 5.824

3.  Haemophilia B is clinically less severe than haemophilia A: further evidence.

Authors:  Massimo Franchini; Pier Mannuccio Mannucci
Journal:  Blood Transfus       Date:  2016-10-04       Impact factor: 3.443

Review 4.  Factor-mimetic and rebalancing therapies in hemophilia A and B: the end of factor concentrates?

Authors:  Patrick Ellsworth; Alice Ma
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2021-12-10

Review 5.  Management of Hemophilia in Older Patients.

Authors:  Massimo Franchini; Pier Mannuccio Mannucci
Journal:  Drugs Aging       Date:  2017-12       Impact factor: 3.923

6.  The European Hematology Association Roadmap for European Hematology Research: a consensus document.

Authors:  Andreas Engert; Carlo Balduini; Anneke Brand; Bertrand Coiffier; Catherine Cordonnier; Hartmut Döhner; Thom Duyvené de Wit; Sabine Eichinger; Willem Fibbe; Tony Green; Fleur de Haas; Achille Iolascon; Thierry Jaffredo; Francesco Rodeghiero; Gilles Salles; Jan Jacob Schuringa
Journal:  Haematologica       Date:  2016-01-27       Impact factor: 9.941

7.  Direct-to-consumer Marketing to People with Hemophilia.

Authors:  Philip Kucab; Katelyn Dow Stepanyan; Adriane Fugh-Berman
Journal:  PLoS Med       Date:  2016-06-14       Impact factor: 11.069

8.  The impact of extended half-life versus conventional factor product on hemophilia caregiver burden.

Authors:  Carolyn E Schwartz; Victoria E Powell; Jun Su; Jie Zhang; Adi Eldar-Lissai
Journal:  Qual Life Res       Date:  2018-02-01       Impact factor: 4.147

9.  In-hospital management of persons with haemophilia and COVID-19: Practical guidance.

Authors:  Cedric Hermans; Catherine Lambert; Amaury Sogorb; Xavier Wittebole; Leila Belkhir; Jean Cyr Yombi
Journal:  Haemophilia       Date:  2020-07-29       Impact factor: 4.263

10.  [A phase Ⅲ multi-center clinical trial on safety and efficacy of a domestic plasma derived factor Ⅸ for the treatment of patients with hemophilia B].

Authors:  W Liu; R F Fu; Y W Zhou; Y Chen; J Yin; Z Q Yu; L H Yang; M F Wang; H Bi; Z P Zhou; X S Zhang; J L Xia; R C Yang
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2018-05-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.